X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs AJANTA PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA AJANTA PHARMA DISHMAN PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 25.1 21.6 116.1% View Chart
P/BV x 3.3 5.1 65.9% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
AJANTA PHARMA
Mar-18
DISHMAN PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,818 20.6%   
Low Rs1291,106 11.7%   
Sales per share (Unadj.) Rs197.8239.5 82.6%  
Earnings per share (Unadj.) Rs21.252.8 40.2%  
Cash flow per share (Unadj.) Rs34.759.5 58.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9230.0 78.2%  
Shares outstanding (eoy) m80.6988.77 90.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.36.1 20.8%   
Avg P/E ratio x11.927.7 42.9%  
P/CF ratio (eoy) x7.224.6 29.5%  
Price / Book Value ratio x1.46.4 22.0%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,306129,782 15.6%   
No. of employees `0000.86.8 12.2%   
Total wages/salary Rs m5,3553,765 142.2%   
Avg. sales/employee Rs Th19,252.73,128.4 615.4%   
Avg. wages/employee Rs Th6,459.5554.0 1,165.9%   
Avg. net profit/employee Rs Th2,064.1689.7 299.3%   
INCOME DATA
Net Sales Rs m15,96121,258 75.1%  
Other income Rs m265242 109.9%   
Total revenues Rs m16,22621,499 75.5%   
Gross profit Rs m4,1036,584 62.3%  
Depreciation Rs m1,091596 183.0%   
Interest Rs m9444 23,034.1%   
Profit before tax Rs m2,3346,226 37.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,539 40.5%   
Profit after tax Rs m1,7114,686 36.5%  
Gross profit margin %25.731.0 83.0%  
Effective tax rate %26.724.7 108.1%   
Net profit margin %10.722.0 48.6%  
BALANCE SHEET DATA
Current assets Rs m11,01812,236 90.0%   
Current liabilities Rs m9,5173,461 275.0%   
Net working cap to sales %9.441.3 22.8%  
Current ratio x1.23.5 32.7%  
Inventory Days Days11060 183.5%  
Debtors Days Days3584 41.2%  
Net fixed assets Rs m16,30411,140 146.4%   
Share capital Rs m161177 91.2%   
"Free" reserves Rs m12,90720,237 63.8%   
Net worth Rs m14,51620,414 71.1%   
Long term debt Rs m4,18910 41,479.2%   
Total assets Rs m29,80524,486 121.7%  
Interest coverage x3.51,519.4 0.2%   
Debt to equity ratio x0.30 58,333.8%  
Sales to assets ratio x0.50.9 61.7%   
Return on assets %8.919.2 46.5%  
Return on equity %11.823.0 51.3%  
Return on capital %17.530.5 57.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95211,667 42.4%   
Fx outflow Rs m6971,616 43.1%   
Net fx Rs m4,25510,052 42.3%   
CASH FLOW
From Operations Rs m2,7862,854 97.6%  
From Investments Rs m-1,529-2,604 58.7%  
From Financial Activity Rs m-941-2 47,055.0%  
Net Cashflow Rs m316248 127.5%  

Share Holding

Indian Promoters % 61.4 73.8 83.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 1.6 238.7%  
FIIs % 12.7 7.6 167.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.0 130.0%  
Shareholders   46,261 20,968 220.6%  
Pledged promoter(s) holding % 35.8 4.4 814.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   CIPLA  PFIZER  NATCO PHARMA  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 17.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, AJANTA PHARMA has posted a net profit of Rs 945 m (down 17.1% YoY). Sales on the other hand came in at Rs 5 bn (up 11.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS